ST. LOUIS, May 20 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today reported on the favorable endorsements of its Niobe(R) Magnetic Navigation System and Odyssey(TM) information management tools received from key opinion leaders in electrophysiology at Heart Rhythm 2008, the Heart Rhythm Society's 29th Annual Scientific Sessions, which concluded on Saturday, May 17.

In his core curriculum presentation, Dr. Xu Chen of the Rigshospitalet -- Copenhagen University Hospital, reported 100% acute success and 92% chronic success, with zero complications, in pediatric supraventricular tachycardia cases performed with the Niobe System. In addition, the remote magnetic navigation system lowered his patients' mean x-ray exposure to only five minutes, which is even more important in the pediatric population to minimize the potential long-term effects of radiation on children. Dr. Chen remarked on the Niobe System's safety, pointing out how the flexible, magnetically-guided catheter significantly reduces the risk of perforation.

Prof. Tamas Szili-Torok of Erasmus Medical Center in Rotterdam reported in a core curriculum presentation that remote magnetic navigation is now the standard of care for pediatric cases at Erasmus, due to its greater safety and ability to navigate complex anatomy. He presented 100% acute success and 81% chronic success in pediatric supraventricular tachycardia cases with the Niobe System at one-year follow-up, and 92% and 75% acute and chronic success, respectively, in the even more challenging congenital heart disease cases, also at one-year follow-up. His patients experienced zero complications related to the Niobe system during these complex procedures.

In all, 90% of the 96 core curriculum sessions presented at Heart Rhythm 2008, including all 33 sessions related to ablation techniques, included presentations delivered by physicians from institutions that have already purchased or ordered a Niobe(R) Magnetic Navigation system.

Speakers at the accredited symposium, "The Integrated EP Lab: The Future of Complex Arrhythmia Ablation," provided their perspectives on the complete array of Stereotaxis technologies, from the remote navigation of magnetic catheters to integrated information management and networking:

Dr. Andrea Natale, of the Texas Cardiac Arrhythmia Institute, endorsed magnetic navigation as an important tool for VT mapping of the endocardium and epicardium.

Prof. Karl-Heinz Kuck of St. Georg Hospital in Hamburg, presented data demonstrating the superior tissue contact that is achievable with magnetic catheters, optimizing safety and lesion formation at low contact forces. He noted that "it is almost impossible to perforate with a magnetic catheter."

While Prof. Carlo Pappone of San Raffaele University Hospital in Milan, Italy, using a Lasso(TM) catheter, confirmed 100% acute success in PV isolation with the magnetic irrigated catheter, the bulk of his remarks focused on the advanced simplification, accelerated learning curve, and improved communication that is now achievable with the Odyssey System and Network.

Dr. Gery Tomassoni of Central Baptist Hospital in Lexington, Kentucky underscored this point, suggesting that Odyssey will be the ultimate tool for the complete integration of existing and emerging technologies in the EP Lab.

"Stereotaxis is committed to improving EP lab efficiency at every point along the continuum of clinical practice, from enhancing the precision, efficacy and safety of remote navigation and consolidating information and systems management in the EP lab, to extending best practices across a growing network of interconnected users," said Bevil Hogg, CEO of Stereotaxis. Mr. Hogg continued, "We were delighted with the broad spectrum of clinical endorsements of our technology in the core curriculum, which represented the principal scientific content of the conference, and we were very encouraged by the enthusiastic reception our Niobe and Odyssey systems received on the conference floor. We believe the conference further underlined the effectiveness of our technology in all four chambers of the heart. With our reputation for safety, simplicity and efficacy reinforced by this extremely successful event, we look forward to our goal of achieving 150 installations and a total of 25,000-30,000 procedures since inception, completed by Heart Rhythm 2009."

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE  Stereotaxis, Inc.
    -0-                             05/20/2008
    /CONTACT:  company, Jim Stolze, Chief Financial Officer of Stereotaxis,
Inc., +1-314-678-6105; or investors, Doug Sherk or Jenifer Kirtland,
+1-415-896-6820, or media, Steve DiMattia, +1-646-201-5445, all of EVC Group,
Inc., for Stereotaxis, Inc./
    /Web site:  http://www.stereotaxis.com /
    (STXS)

CO:  Stereotaxis, Inc.
ST:  Missouri
IN:  HEA MTC
SU:  TRI TDS

MX-SH
-- AQTU048 --
8850 05/20/2008 06:30 EDT http://www.prnewswire.com